Gary J. G. Atkinson
Fondateur chez Zylö Therapeutic, Inc.
Profil
Gary J.
G.
Atkinson founded Zylö Therapeutic, Inc. in 2017, where he is working as Director from 2017.
Mr. Atkinson also formerly worked at Ionis Pharmaceuticals, Inc., as Vice President-Finance from 1995 to 2000, Quorex Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President from 2001 to 2005, and Lpath, Inc., as Chief Financial Officer, Secretary & VP from 2005 to 2012.
Mr. Atkinson received his undergraduate degree from Brigham Young University.
Postes actifs de Gary J. G. Atkinson
| Sociétés | Poste | Début |
|---|---|---|
Zylö Therapeutic, Inc.
 Zylö Therapeutic, Inc. BiotechnologyHealth Technology Zylö Therapeutic, Inc. develops a drug-delivery system designed to deliver notoriously hard-to-deliver therapeutic agents. The frim offers patented platform technology that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration, enabling the healthcare industry to harness the therapeutic potential across a variety of applications. The company was founded by Scott R. Pancoast, Joel M. Friedman, Adam Friedman, Lance M. White and Gary J. G. Atkinsonin November 2017 in and is headquartered in Greenville, SC. | Fondateur | 01/11/2017 |
Anciens postes connus de Gary J. G. Atkinson
| Sociétés | Poste | Fin |
|---|---|---|
Quorex Pharmaceuticals, Inc.
 Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Directeur Financier/CFO | 01/01/2005 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2000 |
Lpath, Inc.
 Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Directeur Général | - |
Formation de Gary J. G. Atkinson
| Brigham Young University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Quorex Pharmaceuticals, Inc.
Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Health Technology |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Health Technology |
Zylö Therapeutic, Inc.
Zylö Therapeutic, Inc. BiotechnologyHealth Technology Zylö Therapeutic, Inc. develops a drug-delivery system designed to deliver notoriously hard-to-deliver therapeutic agents. The frim offers patented platform technology that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration, enabling the healthcare industry to harness the therapeutic potential across a variety of applications. The company was founded by Scott R. Pancoast, Joel M. Friedman, Adam Friedman, Lance M. White and Gary J. G. Atkinsonin November 2017 in and is headquartered in Greenville, SC. | Health Technology |